Inventiva Secures Approval for Prospectus
Inventiva, a clinical-stage biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), recently received crucial backing from the regulatory body, Autorité des marchés financiers (AMF). This came with the approval of a prospectus intended to facilitate financing through the issuance of ordinary shares and pre-funded warrants. This approval highlights Inventiva’s ongoing commitment to addressing significant unmet medical needs in the healthcare sector.
Understanding the Prospectus Details
The approved prospectus outlines several key components necessary for potential investors. Firstly, it includes the universal registration document filed with the AMF earlier this year. Additionally, it encompasses an amendment to the existing universal registration document that complements the essential half-yearly financial report released. These documents collectively provide a comprehensive overview for investors interested in supporting Inventiva's mission.
About Inventiva's Clinical Developments
Inventiva is deeply invested in research and development of oral small molecule therapies targeting MASH/NASH and other diseases. With a robust pipeline, it continues to push forward with innovative solutions to pressing health concerns. The company is particularly advancing its lead product candidate, lanifibranor, which is currently undergoing a pivotal Phase III trial called NATiV3. This trial aims to provide effective treatment options for adult patients suffering from this chronic liver disease.
Lanifibranor's Role in MASH Treatment
Lanifibranor represents a significant step forward for both Inventiva and patients grappling with MASH/NASH. This clinical candidate is at the forefront of the company’s research endeavors and showcases their commitment to enhancing treatment modalities within the biopharmaceutical landscape.
Pipelines and Future Strategies
Alongside lanifibranor, Inventiva also focuses on odiparcil, a candidate aimed at treating adult patients with MPS VI. However, strategic shifts have occurred to prioritize lanifibranor, leading to a suspension of the clinical efforts around odiparcil while the company evaluates potential directions for its further development. Furthermore, there is anticipation regarding the selection of a candidate for its Hippo signaling pathway program, further diversifying Inventiva's innovative approaches to therapy.
Expert Team Supporting Innovation
The strength of Inventiva lies in its dedicated team, comprising about 90 skilled professionals specializing across various scientific disciplines. Their expertise encompasses biology, medicinal chemistry, pharmacokinetics, and clinical development. With a library housing approximately 240,000 pharmacologically relevant molecules, of which 60% are proprietary, Inventiva demonstrates its robust foundation for advancing therapeutic research.
Contact Information for Inquiries
For those interested in learning more about Inventiva's ongoing projects or wishing to invest, the company has made its contact details available.
Inventiva's Contact
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937
Media Relations via Brunswick Group
For media inquiries, interested parties can reach out to the Brunswick Group representatives:
Email: inventiva@brunswickgroup.com
Phone: +33 1 53 96 83 83
Investor Relations by Westwicke
For questions pertaining to investor relations, please contact Patricia L. Bank.
Email: patti.bank@westwicke.com
Phone: +1 415 513-1284
Frequently Asked Questions
What is the purpose of the newly approved prospectus?
The prospectus is intended to facilitate financing through the issuance of ordinary shares and pre-funded warrants for Inventiva's ongoing clinical developments.
What is lanifibranor used for?
Lanifibranor is an experimental treatment being evaluated for its effectiveness in managing metabolic dysfunction-associated steatohepatitis (MASH) in adult patients.
Are there any other drug candidates in Inventiva's pipeline?
Yes, alongside lanifibranor, Inventiva is also working on odiparcil for treating adult MPS VI patients.
How many employees does Inventiva have?
Inventiva employs about 90 skilled professionals specializing in various scientific and clinical fields.
How can I get more information about Inventiva?
For further details, you can contact their media or investor relations, or visit their official website.
